Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
June Lee
AddedFeb 13, 2024
UpdatedMay 31, 2026
June Lee

June Lee

Board Member, GenEdit

CrunchbaseLinkedIn

June Lee's Career

GenEdit
GenEdit

South San Francisco, CA, US

Board Member· Board
Alumis
Alumis

South San Francisco, CA, US

Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

June Lee's Career

GenEdit
GenEdit
Series A$67.7M472016South San Francisco, CA, US
Board Member· Board

Leadership at GenEdit

Kunwoo LeeKunwoo LeeBoard Member
David SchafferDavid SchafferBoard Member
Hyo Min ParkHyo Min ParkCo-Founder
Niren MurthyNiren MurthyCo-Founder
Jiwoong ChunJiwoong ChunBoard Member

Similar to GenEdit

Editas MedicineEditas MedicineCambridge, MA, USGene Editing, Therapiesest. 2013Editas MedicineCambridge, MA, US · est. 2013

Editas Medicine, Inc.: A clinical-stage biotech firm pioneering CRISPR-based therapies for rare diseases.

Public · $931.6M226
SynthegoSynthegoRedwood City, CA, USCrispr Kits, Gene Editingest. 2012SynthegoRedwood City, CA, US · est. 2012

US-based Synthego Corp. provides software solutions for biological research, primarily serving California.

Series E · $460.5M322
Mammoth BiosciencesMammoth BiosciencesSan Francisco, CA, USCrispr Productsest. 2017Mammoth BiosciencesSan Francisco, CA, US · est. 2017

Mammoth Biosciences: An American biotech firm innovating CRISPR products to improve lives.

Series D · $264.5M195
Alumis
Alumis
Series B$270M302021South San Francisco, CA, US
Founder

Leadership at Alumis

Martin BablerMartin BablerBoard Member
Alan ColowickAlan ColowickBoard Member
Michael RomeMichael RomeBoard Member

Similar to Alumis

HI-BioHI-BioSan Francisco, CA, USBiotechest. 2021HI-BioSan Francisco, CA, US · est. 2021

HI-Bio pioneers precision medicine, targeting cellular drivers to treat immune-mediated diseases.

Series B · $215M48
Endpoint HealthEndpoint HealthPalo Alto, CA, USTests, Therapeuticsest. 2018Endpoint HealthPalo Alto, CA, US · est. 2018

Endpoint Health: Personalized therapies for immune-driven illnesses, improving patient outcomes.

Series D · $64.2M
Alphina TherapeuticsAlphina TherapeuticsWestport, CT, USBiotechest. 2020Alphina TherapeuticsWestport, CT, US · est. 2020

Alphina Therapeutics: A biotech firm specializing in precision cancer medicine.

Series B · $16.9M8
ImidomicsImidomicsSan Francisco, CA, USBiotechnology, Drug Discovery, Therapeuticsest. 2015ImidomicsSan Francisco, CA, US · est. 2015

IMIDomics, Inc.: A biotech firm innovating new treatments for immune-inflammatory diseases.

Public · $16.5M23

June Lee's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance Retail

People Similar to June Lee

Frank TerrizziFrank TerrizziBoard Member · MyoCardioCareDavid LevisonDavid LevisonFounder · CardiodxMin KimMin KimCEO · Cardiac InsightLorraine RuschLorraine RuschBoard Member · Clinical Research IOAndrew ThompsonAndrew ThompsonCo-Founder · Spring Ridge VenturesMohamed Sadeq AliMohamed Sadeq AliCo-Founder · Root NYC